Who is on it, and how far along Every drug ChEMBL records acting on POL, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved5 Cabotegravir Cabotegravir SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials62 Dolutegravir Dolutegravir SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials61 Bictegravir Bictegravir SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials40 Raltegravir Raltegravir SponsorMerck & Co. (MSD) ModalitySmall molecule ActionInhibitor Open trials10 Elvitegravir Elvitegravir SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials7 Phase 22 GSK-364735 GSK-364735 SponsorGSK ModalitySmall molecule ActionInhibitor Open trials0 S-1360 S-1360 SponsorGSK ModalitySmall molecule ActionInhibitor Open trials0
The landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Human immunodeficiency virus type 1 integrase inhibitor.
Open trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 28 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness Bictegravir, Cabotegravir Phase 1 Not yet recruiting National Institute of Allergy and Infectious Diseases (NIAID) Nov 16, 2026 Bictegravir Efficacy With 1st INSTI Generation Failure History Bictegravir — Not yet recruiting Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba Nov 12, 2026 Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Bictegravir — Recruiting Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida Nov 6, 2026 Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV Bictegravir, Cabotegravir, Dolutegravir Phase 4 Not yet recruiting Gilead Sciences Nov 2, 2026 Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment Dolutegravir Phase 2 Recruiting Federal University of São Paulo Oct 29, 2026 Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI Study Cabotegravir Phase 4 Not yet recruiting University of North Carolina, Chapel Hill Oct 26, 2026 Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO). Bictegravir — Not yet recruiting Ente Ospedaliero Ospedali Galliera Oct 6, 2026 Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels Bictegravir Phase 2 Recruiting Gilead Sciences Sep 25, 2026 A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants Cabotegravir Phase 1 Recruiting ViiV Healthcare Sep 14, 2026 A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY) Cabotegravir, Dolutegravir Phase 2 Not yet recruiting ViiV Healthcare Sep 11, 2026 An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir Phase 3 Not yet recruiting University College, London Aug 28, 2026 Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma Bictegravir, Cabotegravir Not applicable Recruiting Shanghai Public Health Clinical Center Jul 27, 2026 Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1) Dolutegravir Phase 1 / Phase 2 Recruiting Jiangsu Aidea Pharmaceutical Group Co., Ltd. Jul 17, 2026 Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment Bictegravir Phase 2 / Phase 3 Recruiting Gilead Sciences Jul 16, 2026 Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. Cabotegravir — Active, not recruiting FUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTE Jul 14, 2026 Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy Cabotegravir Phase 3 Recruiting Gilead Sciences Jul 6, 2026 Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens Dolutegravir Phase 3 Recruiting Gilead Sciences Jul 6, 2026 Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV Dolutegravir Phase 4 Not yet recruiting University of Witwatersrand, South Africa Jun 29, 2026 Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women Dolutegravir Phase 4 Recruiting Fundación Huésped Jun 1, 2026 Research on the Psychological Status of Patients With HIV-1 Infection Elvitegravir, Raltegravir — Not yet recruiting Shanxi Bethune Hospital Jul 23, 2025 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 Elvitegravir, Raltegravir Phase 3 Active, not recruiting Gilead Sciences Oct 8, 2024 Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses Elvitegravir, Raltegravir Phase 2 Not yet recruiting ANRS, Emerging Infectious Diseases Apr 1, 2024 A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments Elvitegravir, Raltegravir Phase 4 Recruiting Gilead Sciences Mar 29, 2024 B-free Multistage Trial Elvitegravir, Raltegravir Phase 4 Enrolling by invitation Insel Gruppe AG, University Hospital Bern Sep 14, 2023 Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) Elvitegravir, Raltegravir Phase 2 / Phase 3 Active, not recruiting Gilead Sciences Aug 16, 2022 Kuwa Free! - Live Free! Raltegravir Not applicable Recruiting University of Alabama at Birmingham Sep 16, 2021 HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label Raltegravir Phase 2 Recruiting Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida Aug 14, 2020 Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV Elvitegravir Phase 2 / Phase 3 Active, not recruiting Gilead Sciences Dec 20, 2013
Show all 28
Genes and related targets Complexes and families that share a gene with this target
Genes POL Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3471 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. ChEMBL and Open Targets